Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report
Abstract
Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study
Steroid-refractory GvHD (SR-GvHD) following allogeneic transplant is a major clinical challenge and is associated with substantial mortality [1].
Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML
SRSF2-mutated MDS: bortezomib STAT?
In this issue of Blood, Takashima et al show that reduced STAT1 abundance in SRSF2-mutant myelodysplastic syndrome (MDS) cells confers protection against interferon (IFN)-driven cell suppression relative to normal wild-type (WT) cells.1 Importantly, the authors demonstrate that treatment with the proteasome inhibitor bortezomib in vitro increases STAT1 abundance and sensitizes SRSF2-mutant cells to IFN. These findings provide potential rationale for using bortezomib therapy in SRSF2-mutated MDS, which is characterized by poor outcomes.
Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy
Abstract
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency
Abstract
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Abstract
Purpose